DAX23.640 -1,4%Est505.795 -0,7%MSCI World4.343 -0,1%Top 10 Crypto9,1400 -2,0%Nas22.716 +0,1%Bitcoin60.455 -0,6%Euro1,1556 ±0,0%Öl95,68 +2,2%Gold5.185 +0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 BioNTech (ADRs) A2PSR2 Lufthansa 823212 SAP 716460 NVIDIA 918422 Siemens Energy ENER6Y DroneShield A2DMAA Volkswagen (VW) vz. 766403 Bayer BAY001 Allianz 840400 Gerresheimer A0LD6E Deutsche Telekom 555750 Novo Nordisk A3EU6F RENK RENK73 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Ölpreise steigen wieder: DAX tiefer erwartet -- Verluste in Asien -- RWE mit Gewinnrückgang -- Zalando wächst kräftig und kauft eigene Aktien zurück -- BMW mit Umsatz- und Gewinnrückgang
Top News
Jetzt bei Kraken starten und 30 € Willkommensbonus sichern Jetzt bei Kraken starten und 30 € Willkommensbonus sichern
Suchst Du einen Online-Broker, der mehr bietet? Clever und flexibel traden mit finanzen.net ZERO Suchst Du einen Online-Broker, der mehr bietet? Clever und flexibel traden mit finanzen.net ZERO
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Takeda Pharmaceutical Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
30,80 EUR -0,17 EUR -0,55 %
STU
30,69 EUR -0,39 EUR -1,25 %
GVIE
finanzen.net zero
Takeda Pharmaceutical jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.49,57 Mrd. EUR

KGV64,56Div. Rendite4,44%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN853849

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINJP3463000004

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTKPHF

Takeda Pharmaceutical Aktien News

DatumMeistgelesen
PR NewswireBritish Columbia reimburses FRUZAQLATM (fruquintinib capsules) for the treatment of metastatic colorectal cancer (mCRC)
PR NewswireTakeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)
PR NewswireTakeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)
Wer­bungTakeda Pharmaceutical-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireTakeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
PR NewswireTakeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
PR NewswireThe European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Heredit...
PR NewswireDie Europäische Arzneimittelagentur (EMA) hat eine zusätzliche Option zur subkutanen Verabreichung von TAKHZYRO® (Lanadelumab) für Patienten ab 12 Jahren mit wiederkehrenden Attacken des hereditär...
PR NewswireThe European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Heredit...
PR NewswireTakeda Recognized as a Top Employer in Canada for Third Consecutive Year
PR NewswireTakeda Recognized as a Top Employer in Canada for Third Consecutive Year
PR NewswireTakeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)
PR NewswireTakeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)
PR NewswireTakeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative
PR NewswireTakeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative
PR NewswireNew Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
PR NewswireNew Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
PR NewswireVatroslav Mateljic Appointed General Manager of Takeda Canada
PR NewswireVatroslav Mateljic Appointed General Manager of Takeda Canada
PR NewswireTakeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
PR NewswireTakeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
EQS GroupEQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
PR NewswireNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
PR NewswireTakeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
PR NewswireEmpathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
PR NewswireEmpathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
PR NewswireTakeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.
PR NewswireChampioning Rare Voices on Rare Disease Day
PR NewswireChampioning Rare Voices on Rare Disease Day
PR NewswireCognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
PR NewswireTakeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of Emphysema
PR NewswireTakeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of Emphysema
PR NewswireThe European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
EQS GroupEQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)
PR NewswireTakeda Receives Corporate Leader Award from the Daily Bread Food Bank
PR NewswireTakeda Receives Corporate Leader Award from the Daily Bread Food Bank
PR NewswireTakeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data
PR NewswireTakeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data
PR NewswireTakeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
PR NewswirePatient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge
PR NewswirePatient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge

Takeda Pharmaceutical News

Takeda Pharmaceutical News: auf dieser Seite finden Sie alle Takeda Pharmaceutical News und Nachrichten zur Takeda Pharmaceutical Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Takeda Pharmaceutical News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Takeda Pharmaceutical News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.